Summary
A review of the published evidence presented here argues that screening for melanoma is recommended and practised at present, but with wide diversity of opinions about its value; there is evidence that screening has considerable potential for benefit, but the evidence of actual benefit is limited; and there are substantial costs and potential hazards from screening.
On this basis the evaluation of screening procedures for melanoma is important, and options for this are discussed. The ideal study design to assess the efficacy of melanoma screening in reducing mortality is a large scale randomised trial. This may need a well coordinated proposal involving several centres in one or more countries, and the cost would be substantial. Without such a trial, bow-' ever, it is most likely that increasing resources will be put into poorly designed screening programmes of unknown value.
The simplest and strongest designs use individual randomisation, but group randomisation designs may have practical advantages, though they require a greater sample size. Designs based on general population screening, and on screening only high risk groups, are both considered. They answer different questions. In countries with high incidence the value of general population screening is probably the more critical. Not enough is known to specify the type and frequency of screening precisely; both screening by doctors and self screening require evaluation, and annual screening should probably be tested. The age range at risk will depend on the local incidence, but is likely to be quite wide -for example, 45-69, and both sexes need inclusion. Thus a suggested design for a moderate to high incidence area would be a trial, randomised by individual or group, assessing at least two annual rounds of both screening by doctor and self screening (ideally by a factorial design), for adults aged 45-69, with mortality over several years' follow up as the critical outcome. In an area with good data systems such a study could compare screening offered to some 260000 subjects with 10 times that number of controls passively followed up, with 90% power to detect a one third reduction in mortality. A general assessment of costs over five years gave estimates of5S.3 mil-lion for the screening programme and 52.4 million for the evaluation.
The much weaker designs, area based cohort studies using individual data or a simpler ecological comparison, and casecontrol studies, are also considered. If well designed with attention to their methodological limitations they may be valuable but are unlikely to be as definitive as a randomised trial.
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USE OF SCREENING, AND RECOMMENDATIONS OF INFLUENTIAL GROUPS
Screening is recommended and practised at present, but with wide diversity of opinions about its value. Regular examination of skin by a doctor and self screening are advocated by the American Cancer Society (3294), the National Cancer Institute (US),! and the American Academy of Dermatology." The American Cancer Society and the American Academy of Dermatology recommend self screening and have published detailed methods of how this might be done. Friedman et al, writing in conjunction with these two American organisations, conclude that "a complete annual examination of the skin by a physician is recommended for everyone, supplemented by monthly self-examinations by the patient. Patients with a personal or family history of malignant melanoma, as well as those with dysplastic nevi or any of the other risk factors, should have more frequent examinations by both their physicians and themselves"."
In contrast, general population skin screening is not recommended by the Canadian Task Force on the Periodic Health Examination or the US Preventive Services Task Force;" both groups basing their recommendations on a critical review of published evidence. Both groups, however, recommend skin examinations for high risk groups; the United States group recommends screening by complete skin examination for "persons with a family or personal history of skin cancer, clinical evidence of precursor lesions (e.g. dysplastic nevi, certain congenital nevi), and those with increased occupational or recreational exposure to sunlight". These categories, especially the last, could include a substantial proportion of the population. General population screening is not recommended by the Australian Cancer Society," or by the International Union Against Cancer, which has recently published a melanoma control manual. 7 The NIH Consensus Development Panel on Early Melanoma concluded that "there is sufficient evidence to warrant screening programmes for melanoma in the United States"." The justification for this conclusion is not made clear, however. Indeed, there is no evidence given for the effectiveness, as distinct from the potential effectiveness, of screening. The only evidence quoted is "preliminary evidence from uncontrolled trials in countries such as Scotland"; it will be shown below that the studies in Scotland do not assess screening but are studies of educational programmes. The NIH group conclude that "there is a reliable screening test" and other conditions for potential benefit, but also note that a randomised trial has not been done, and that "the primary care medical community is not yet adequately prepared for undertaking or responding to patient-screening programmes".
In the most detailed available population based survey in New South Wales, Australia, 17% of 1344 subjects had had a skin examination from their family practitioner in the previous year, and 48% reported having used self screening." This is a high prevalence, but there is no information on the thoroughness or regularity of screening. In Connecticut preliminary results of a case-control study show that 27% of controls report that they have ever conducted a purposeful skin examination of themselves.'? In Massachusetts in 1986, 20% of patients with melanoma reported having had regular skin examinations by a doctor, and 24% reported regular skin self examination. 11 Self assessment is being encouraged in many countries by public education campaigns, which often have mixed objectives, aiming at the one time to (a) prevent melanoma by giving advice about sun exposure and its reduction; (b) to encourage a rapid response to suspicious lesions which the subject has already noticed by emphasising the importance of seeking medical advice for skin lesions which have certain "danger" signs; and (c) to encourage the recognition of the early signs of melanoma by giving advice about these signs, and by encouraging people to inspect their own bodies and perhaps those of families and close friends. These education campaigns are often related not only to melanoma but to other skin cancers. Assessment of the objectives and the outcomes of these programmes is difficult and has not been undertaken in any detail.
POTENTIAL BENEFIT FROM SCREENING
The survival rate after diagnosis of melanoma varies dramatically according to the depth of the tumour at diagnosis, the range being from 30% survival 10 years after diagnosis for tumours over 4 mm thick to 87% for those less than 0·76 rnm." Survival rates have improved over time, and several detailed analyses suggest that this improvement is largely or totally due to earlier diagnosis. 1213 Survival rates are generally higher in countries with higher incidence of melanoma, and this is also largely or totally owing to earlier diagnosis. Of 23 melanomas diagnosed in South Australian patients during 1980-4, 43% were less than 0·76 mm thick, and the overall survival rate at four years was 87%.14 This variation in survival after diagnosis depending on the depth of invasion provides good a priori evidence that earlier diagnosis may be effective in reducing mortality. It is well recognised, however, that this does not prove a benefit for early diagnosis. It has been suggested that the differences in survival by time and place may be due to environmental factors producing a less aggressive type of disease." Biases due to selection factors, lead time, and prevalence duration biases can produce the situation where patients diagnosed through early diagnosis programmes will have smaller, less clinically advanced lesions and greater survival rates after diagnosis, without there necessarily being any true increase in survival or reduction in death rate."
Screening programmes for melanoma can also detect many other lesions, including nonmelanoma skin cancers and dysplastic naevi. There may be advantages to this, in that earlier intervention may lead to less morbidity after non-melanoma skin cancers or the detection and removal of precancerous lesions. But there seem to be no data on which the extent of such benefits can be judged.
DOCUMENTATION AND EVALUATION OF SCREENING PROGRAMMES AND RELATED ACTIVITIES
Evidence for the impact of professional and public education programmes Good evidence on educational programmes comes from the work of MacKie and her colleagues in Scotland. After demonstrating the poor depth distribution and delay behaviour in Glasgow in 1979-83 17 a pigmented lesion clinic was established to facilitate referral, and an educational programme was offered first to general practitioners and then to the public in May 1985. This produced an increase in the total number of melanomas diagnosed, and from 1985 to 1990 an increase in the proportion of thinner lesions « 1·5 mm) in Scotland, even after adjustment for sex, site, age, and type." More importantly, there was a decrease in both the population based incidence of lesions greater than 1·5 mm and in mortality, in women but not in men. IS The Scottish studies relate to an educational programme, backed up by education of primary care doctors and a rapid referral service. They do not relate to population screening, and it is incorrect to apply these results to screening, as has been done in the NIH consensus conference."
The limitation of the impact of these campaigns on women may be due to social or biological factors; Mackie notes that reinforcement of the educational messages is mainly in media, such as magazines more often read by women, and that screening programmes for cervix and breast cancers provide precedents for attention to early cancers by women." The trends in mortality in Scotland are similar to those in Sweden," though the possible role of specific educational programmes there has not been discussed.
Following the Glasgow lead, programmes were established at seven other centres in the United Kingdom. In the two areas reporting results there was a shift towards a lower proportion of melanomas with poor prognosis, owing to a rise in the frequency of diagnosis of thin tumours and in situ cases rather than to a reduction in advanced cases. 21 22 The Nottingham data show that of patients diagnosed after the campaign, 48% reported that their lesion had been present for more than a year, and in only three cases was the first recognition of an abnormality, as distinct from action taken for an existing lesion, attributed to the campaign."
In Trentino, northern Italy, a campaign also based on education of doctors followed by public education campaigns in 1977 and 1981 has been evaluated. 23 During 1972--6 and 1982-5 the mortality in men and women increased by 44% and 19% respectively in Trentino, compared with 116% and 76% in neighbouring Lombardia.
The authors showed that if the difference is due to the programme the health service costs saved easily outweighed the costs of the programme, and the cost per year of life saved was only $400.
In Australia a television documentary based on a young patient who was dying from rnelanoma was shown on a peak time current affairs programme and produced great interest and an increase in referrals for melanoma in the subsequent weeks; it was estimated that some 750 melanomas were diagnosed as a result (McCarthy, personal communication). Data from a large pathology laboratory in Victoria show that in three months after the programme, 126 melanomas were diagnosed with a mean thickness of 0·63 mm, compared with 53 melanomas with a mean thickness of 1·61 mm diagnosed during the same months a year earlier (Anti-Cancer Council of Victoria, unpublished data). However, a subsequent similar programme had a much less dramatic impact."
Evaluation of open access skin check programmes
In many countries, such as the United States, Canada, Australia, and New Zealand, simple "skin check" sessions have been set up to make it easy for members of the public to obtain a clinical opinion on a lesion they regard as suspicious, and to provide a screening examination and education about early diagnosis and prevention. Evaluation of these programmes has been usually crude. Often only total numbers of subjects presenting and the number of potential skin cancers diagnosed have been reported. There are also some quite difficult methodological issues. Many subjects attending such clinics will be unaware of any suspicious sign or symptom, and so the examination can be regarded as a screening examination. As those attending are a small proportion of the eligible population, however, and have Elwood been alerted by publicity and educational campaigns, the data obtained will not predict the situation in population based screening. Also, many attendees will have specific lesions that they are concerned about, and for these the results relate to the use of the clinics as referral rather than as screening clinics. Difficulty in separating these effects and the lack of a population base compromise the interpretation of these data.
The most detailed reports relate to programmes in the United States. The most thorough and critical review of screening programmes of various types in the United States is given by Koh et al. 25 This review shows the application of methodological principles to skin cancer screening, and also shows the limitations of the available data; the authors emphasise these limitations and make useful suggestions for improvement. Of six studies reviewed which give information on the sensitivity, specificity, and predictive value of visual skin examination, three were published over 35 years ago, and two more recent studies apply only to non-melanoma skin cancers. Only the study of Kopf et a [26 in 1975 is reasonably recent and includes data on melanoma; here examination by skin cancer specialists yielded values for all skin cancer of sensitivity 77%, specificity 99%, and predictive value 80%. These values are excellentsimilar or superior to the performance of some accepted screening tests, such as mammography. However, such data based on examinations by a specialist team in a hospital setting, of patients already referred by other doctors, are almost certainly higher than would apply in a screening programme. As Koh et al note, no data are available on the test performance in a general population, or on interobserver variation, or the performance of the examination in other clinical situations.
Koh et al identified nine studies of skin cancer screening in the United States. Most of these are uninformative about melanoma, and none gives both the numbers of suspected and of confirmed melanomas, or has the follow up data necessary to calculate sensitivity and specificity. Only one of these studies relates to a defined population"; the others are studies of subjects who chose to come to a screening facility, with little or no data on the population at risk. Koh et al make these limitations clear, and conclude that "many crucial questions about the proper methods and ultimate value of screening remain unanswered".
In a detailed report Koh et al review the results of skin checks sponsored by the American Academy of Dermatology in Massachusetts in 1986-7; S3 volunteer dermatologists took part in 14 centres, and 2560 subjects came forward for screening." Koh et al used postal and telephone follow up to ascertain outcome. Of the 2560 subjects screened, 787 (31 %) had an abnormal examination and were asked to see their dermatologist or family doctor for follow up. Of these, 26 were suspected of having melanoma, compared with 26 with (suspected) squamous cell carcinoma (Scq, 210 with basal cell carcinoma (BCq, 170 with dysplastic naevus, 27 with congenital naevus, 288 with actinic keratoses, and 40 with other conditions. This raises a major problem with skin cancer screening. If it is started primarily because screening for melanoma is likely to be valuable, it is difficult, and perhaps impossible, in countries such as the United States to avoid referring people for other conditions for which the benefit of earlier diagnosis is unknown. The 31 % referral rate is extremely high and demonstrates the considerable costs to the health care system or to those being screened which arise from such procedures. The criteria for referral from the American Academy of Dermatology programmes are under review, however, and in future, subjects with senile keratoses, for example, may not be referred (Koh HK, personal communication) . This change would reduce the referral rate to 19%. Of those clinically regarded as abnormal, data documenting referral and treatment were obtained on 63%; 22% did not seek help from a dermatologist or a family doctor, and 15% did not respond to the follow up attempts of the investigators. Only about 3% of screened subjects were referred for suspected melanoma. Of the 26 subjects with a suspected melanoma, no follow up information was available on four. In all subjects followed up there were nine confirmed melanomas; it is not clear if all these occurred in the subjects in whom melanoma was clinically suspected. If they did, the predictive value in those classified as suspected melanoma and followed up is 9/22 (41 %), a very high figure in comparison with most screening tests, and must be at least 9/26 (35%). But if the whole programme is justified as a melanoma screening programme, the predictive value in those with follow up information is only around 2%. Obviously the recognition and follow up of other lesions may be of some value, but it is also true that most of these other conditions have an excellent prognosis and require only simple treatment even when managed routinely, so the argument for melanoma screening needs to be made primarily for that disease.
As the authors point out, sensitivity and specificity cannot be calculated from these data. They estimate sensitivity at 97% for melanoma, by using the number of melanomas expected using general population incidence figures and assuming a duration of melanoma of two years as an estimate of the false negative rate, which assumes that "the extra risk among persons who chose to be screened exactly offsets the ability of dermatologists to make a correct diagnosis".28 This can therefore be taken only as an approximate estimate.
Those who come forward for screening are not typical of the population. Koh et al show that in the Massachusetts programme 73% of attendees came to have a specific lesion checked; 36% reported having a changing mole." Eleven per cent had a previous skin cancer and 3% had a previous melanoma, these figures rising to 22% and 7% respectively in those over the age of 60. Seven per cent had attended a previous skin cancer screening. Participants tended to be overrepresented by 25 women, white subjects, and well educated subjects. While these self selection characteristics have a favourable effect in selecting subjects at higher risk, this selection effect would be expected to diminish as screening programmes increase in scale; the effect of less selection will directly reduce the predictive value but probably also change the sensitivity and specificity, as the features of the lesions presented may change.
Koh et al conclude that the yield of screening (for skin cancer in general, not only melanoma) is equivalent to that of other major cancer screening programmes, though they emphasise that more studies are needed to establish the value of screening in reducing morbidity and mortality." Evaluation with more complete follow up will be valuable and is currently being carried out by the Australian Academy of Dermatology (Koh HK, personal communication). Further data show that almost 90% of the first 280 screen detected melanomas were < 1·5 mm, and of all screen detected cases, 1·4% had stage 2 or 3 disease, compared with 6·6% from national Surveillance Epidemiology and End Results registry data."
These data suggest that a major effect of these skin check clinics is to function as diagnostic clinics for people who have already noted something which they regard as abnormal, and who are using the clinic as an alternative or a supplement to normal health care. This will greatly increase the yield from such programmes, and may well be regarded as appropriate. If so, the benefits should be argued on their own merits, and these programmes should not be regarded as the same as general population screening programmes; in particular, the estimates of yield, predictive value, and other variables cannot be directly extrapolated to general population screening.
In West Virginia 799 subjects were screened at a medical centre, and 153 (19%) referred for suspect skin tumours, dysplastic or congenital naevi." Compliance to follow up was 54%, and 31 BCC, three SCC, and two melanomas confirmed. The authors give the predictive value for melanoma as 15%, using as denominator those with suspected melanoma, but again the predictive value of the programme for melanoma is 2/153 (1'3%).
Data from other countries are more limited. In the Netherlands 3069 subjects were checked in four days in a beach trailer in summer 1989 32 ; 65 subjects (2'1 %) were referred to their general practitioner for further care, and 80% of these complied. Results of 46 biopsies were recorded, including six melanomas, two SCC, 23 BCC, five dysplastic naevi, and 10 benign lesions. The positive predictive value is quoted as 83%, but this is not defined. Based on all subjects screening positive the predictive value for all malignancies is 31/65 (48%), and for melanoma is 9%, both quite high. In another report from the Netherlands 2564 subjects were screened, 103 (4'0%) referred, compliance with referral was 90%, and 53 subjects had melanoma or nonmelanoma skin cancer, giving a predictive value of 51 %. 33 The much lower referral rate in these than in the American studies is notable and of considerable importance: it may relate to the different age of the subjects screened, but is likely also to relate to the aims of the programme and the extent to which it is felt that referral has to be made for less marked lesions.
Evaluation of screening programmes of a defined population
There are few studies which report results from screening campaigns in a defined population. The most detailed is a research study in Geraldton, Western Australia," in which 4176 subjects, 76% of all adults aged 40-64 on the electoral roll, were examined by a dermatologist (excluding underwear and hair areas). There were 920 clinically identified cancers, suspicious pigmented lesions, Bowen's disease, and keratoacanthoma; of 39 suspected melanomas, 36 were assessed pathologically and 12 (33%) confirmed; a further eight melanomas were confirmed in lesions clinically classified as BCC or "suspicious pigmented lesions" .
Zagula-Mally et al arranged for nurses to visit households in rural Tennessee and examine the exposed skin of 978 white persons." The total number of subjects at risk is not reported. They found 48 suspicious lesions (that is, suspicious of any type of skin tumour), of which pathology reports were available on only nine, showing six non-melanoma skin cancers. No melanomas were found or suspected.
Other possibilities of regular examination in a defined population include workplace screening. Raphael reports occupational screening examinations of 7450 working women in Australia, with the finding of one melanoma in addition to 18 breast cancers and 273 abnormal Pap smear results."
The most comprehensive and thorough education and early diagnosis programme is that carried out at the Lawrence Livermore National Laboratory in the United States over the past few years," which was set up in response to a suspected increased incidence of the disease. Since 1974, when high awareness of risk from melanoma within the workforce was accompanied by freely available, on site dermatological examinations, the five year survival after diagnosis of all melanomas has been 100%. Thus within the limitations of the size of the group studied complete avoidance of death from melanoma has been achieved.v " The costs of this programme are, however, around $150 000 a year for 10 000 subjects, and so could not easily be replicated on a large scale."
Screening for insurance examinations would seem to be another method, often requiring a more systematic examination, but results of this in terms of skin cancer have not been reported.
Elwood

PERFORMANCE CRITERIA FOR THE SCREENING TEST
Great difficulty arises with the definition of a suitable test -that is, one which is simple and capable of rapid application; acceptable in terms of inconvenience, discomfort, and risks; reproducible in its results; and with known validity and performance characteristics." The main test advocated is a regular examination of the skin by a doctor. In routine clinical practice this requires some 5-15 minutes if done thoroughly, with complete undressing. At least the normal consultation fee for a family doctor would be necessary, and perhaps a further charge given the length of time required.
Apart from the reports noted above, there is little available information about reproducibility and validity. Research studies aiming at high reproducibility in counting naevi, or assessing dysplastic versus normal naevi, have shown that interobserver variation in the assessment of pigmented lesions is considerable. 263941 There is some research which assesses what measures should be emphasised during a general skin examination. Available data on the site distribution of melanoma show that only 15% of melanomas, excluding lentigo maligna melanoma, are likely to be found on fully exposed sites, and 49% are on sites conveniently examined (head and neck, upper limb, and leg). More directly, in a "screening clinic", in which full examination was used, Rigel et al report that only one of 14 lesions discovered would have been found by partial examination."
While clinical skin examination is the procedure, the screening test involves the definition of lesions for which definite action (biopsy or specific follow up) is undertaken. Clinical experience of melanoma has resulted in a number of lists of early signs and symptoms of melanoma, such as the A, B, C, D, E (Asymmetry, Border irregular, Colour mixed, Diameter greater than 6 mm, Elevation) list used by Fitzpatrick and others in the United States," and the seven point check list suggested by MacKie in Glasgow." These are put forward as clinical guides, but their usefulness is limited. The A, B, C, D, E list consists of five factors which are regarded as suspicious signs in a pigmented skin lesion, given that the patient has already taken the initiative of going to a doctor. Decision criteria related to the presence of one, several, or all of these signs have not been specifically tested. The Glasgow checklist is more specific as it is intended for use by general practitioners; patients who have lesions in which three or more of the seven signs or symptoms are present should be referred for a specialist opinion. This checklist has since been revised"; the current recommendation is that all patients with one or more of the "major signs" of change in size, shape, or colour should be considered for referral, and the presence of "minor signs" of inflammation, crusting or bleeding, sensory change, or diameter over 7 mm, should also encourage referral.
In Nottingham (England), of 23 melanomas detected in a specific population over a given time period, 21 had at least three of the seven signs, whereas in all patients referred for a hospital opinion 326 out of 861 patients without melanoma had these signs." Thus the sensitivity is 91 %, specificity 62%, and positive predictive value 6·4%. But these figures relate only to the assessment by a specialist clinic of patients referred by their general practitioner and would probably be overoptimistic if applied to all patients visiting a general practitioner.
Du Vivier et al report data on 100 cases of melanoma seen in a London hospital department following the same educational campaign." Fifty per cent of these tumours were less than 10 mm, and 15% less than 5 mm in diameter; 73% were less than 1·5 mm thick and nearly half of the subjects presented at the insistence of relatives or friends or because of their general practitioner's incidental diagnosis. Half of the patients scored less than three on the Glasgow checklist, and these authors comment that nodular lesions, in particular, might have been misdiagnosed.
An important issue is the prevalence in a general population of the early signs of melanoma given by various authorities. The only reliable data are from New South Wales,946 where 12% of the 1344 respondents had noticed changes of the A, B, C, D, E type in the previous year; 6·8% had sought medical advice, 3·2% had had a biopsy, and 0·5% had had a melanoma diagnosed. The positive predictive value of having any of these signs of melanoma was therefore 4·2%.
DATA ON PRESENTATION AND DIAGNOSIS OF MELANOMA
Recently, Koh et al obtained data on the mode of detection of melanoma from 216 (48 %) of the 454 cases of melanoma reported to the Massachusetts registry in 1986. 11 Of these, 53% were self discovered, 19% first noted by another family member, and 25% by a doctor. Detection by a doctor was greater in men and in older subjects. Strikingly, 23% of melanomas in men were first noticed by their wife (and the proportion was higher for the younger men), but only 2% of lesions in women were first noted by their husband. Thus the proportion of melanomas self detected was higher for women (66% v 42% in men).
These figures are not greatly different from those in two studies from several years ago. In western Canada in 1979-81 14% of melanomas were recognised by a doctor before the patient had noticed anything wrong and a further 25% were noticed by a lay person other than the patient, usually a family member." Melanomas detected by doctors or other lay persons were thinner than those first recognised by the patients themselves. In Queensland in 1979-8023% of melanomas were first recognised by doctors and 20% by other lay people." These high proportions indicate the potential value of simple screening -that is, inspection of skin by health professionals or by relatives or friends 27 of the subject. Family members and health professionals, as well as the subject themselves, clearly playa part in the discovery of melanoma. Further work, assessing in particular the first recognition of early melanoma, will be useful. In the western Canadian study 651 subjects were asked in an unprompted question about the first indications of the melanoma which was ultimately diagnosed." Four changes were most commonly present (enlargement, colour change, pain or bleeding, relating to a naevus, were noted by 65% of subjects), and a small proportion of melanomas arose from what the patient regarded as new moles.
SELECTIVE SCREENING OF HIGH RISK SUBJECTS
Naevi -simple or dysplastic -are the single strongest indicators of melanoma risk. The NIH family studies in the United States show that subjects with a family history of melanoma as well as a personal history of dysplastic naevi have an extremely high subsequent risk of melanoma." In an assessment based on material published up to 1987 the importance of this group, in terms of the whole population, seems to be small. 50 In the 14 families studied, each having at least two members with melanoma, family members who had dysplastic naevi had a relative risk of 148 and a prospectively measured absolute risk of 7·2% over eight years, based on 77 subjects, 398 personyears of follow up (average 5·2 years per subject), and four observed melanomas versus 0·027 expected. The eight year cumulative risk has 95% two sided confidence limits from 0·14 to 14%. Further data have been published in less detail," and a reassessment of this evidence is due.
The central issue here is the prevalence in the whole population of subjects with a combination of a family history of two or more relatives with melanoma and the presence of dysplastic naevi. The NIH group estimated this as 0·014% of the population," and their data gave an incidence of melanoma of 1005/ 100000 a year (about 1%) in such subjects. Consider a population of one million in a high risk area, giving in total some 200 new cases of melanoma a year. If the NIH rate is used there will be 140 (0'014%) subjects at high risk who will have an expected annual number of 1·4 melanomas. Thus although the identification and surveillance of such subjects may be important for research and may be useful for those subjects, it will not make a major impact on the whole problem of melanoma.53 These conclusions could, of course, change as better information about the risks, and particularly the prevalence, of this and other high risk states becomes available.
Subjects who are at the greatest risk are those with a strong family history and a personal history of dysplastic naevi. Follow up studies have shown that selection of such subjects, intensive surveillance by regular clinical examinations -for example, every six months using photography as an aid to the detection of changing lesions, with excisions of lesions which are showing changes -can be an effective method of achieving earlier diagnosis. 54 In the NIH and other studies no increased risk was seen in members of these families who did not themselves have dysplastic naevi. Patients who have already had a melanoma are at an increased risk of subsequent new tumours, and if they also have this strong family history and dysplastic naevi their risk is very high: 33% at eight years." Such subjects should already be receiving good follow up, however, for their first melanoma.
MacKie et al report on a five year follow up of 116 high risk patients in Scotland. 55 In 85 patients with three or more atypical naevi, over 20 benign naevi, but with no personal or family history of melanoma, 583 person-years of follow up yielded five invasive melanomas, compared with 0·054 expected; relative risk = 92, in addition to four level 1 or in situ lesions. A similar relative risk (91) was seen in 24 subjects with atypical naevi and a personal history of melanoma, and a higher risk (444) in seven subjects with atypical naevi and a family history of melanoma. These authors conclude that the incidence of melanoma in subjects with atypical naevi is high, compared, for example, with the risk for breast cancer in age groups for whom screening is advocated, and that surveillance is likely to lead to earlier diagnosis; of the 15 melanomas found on surveillance, eight were 0·7 mm or less, five between 0·8 and 1·5 mm, and two over 1·5mm.
Dysplastic naevi raise two issues in regard to screening. If they are regarded merely as a risk indicator they can indicate which subjects should be regularly assessed for developing melanoma. If they are a precursor a more direct relation holds, and the detection of dysplastic naevi and their removal should effectively reduce the incidence of melanoma, particularly if there were some way of distinguishing between the few dysplastic naevi which will develop further in a reasonable time from the probable much larger number which will not. A research priority is, therefore, to set up studies to attempt to assess the progression potential of dysplastic naevi and to classify more clearly those with a particularly high risk of progression. This may open up the way to further surveillance and follow up procedures. Such methods might include careful clinical description of lesions; the use of non-invasive techniques, such as special lighting, stains, or magnification examinations, and computer imaging techniques; or the use of other markers, such as monoclonal antibodies or genetic markers. Pathological indicators are of much less value as they require biopsy of the potential lesion.
A considerable number of other risk markers for melanoma can be considered. These include a family history of melanoma in at least one relative, which gives a relative risk of 2_5,56 and the presence of dysplastic naevi without a family history of melanoma, which confers a relative risk of around 7. 51 56 These, however, are lower than the risks given by several other simpler measures. Epidemiological studies of Elwood melanoma have involved interviewing and examining patients and unaffected control subjects in their own homes by a lay or nurse interviewer. In these circumstances only a limited examination is possible, and reliable and simple methods have been developed. These can be shown to be as good at defining high risk subjects as some more complex methods, such as whole body examination by dermatologists and assessments of dysplastic naevi. 50 For example, in two British studies the risks of melanoma in subjects who (a) had three or more palpable naevi on the upper arm, assessed by a lay interviewer," or (b) had 50 or more naevi greater than 2 mm in diameter on the whole body, assessed by a dermatologist, were in absolute terms very similar. 58 In Australia subjects who (a) had five or more palpable naevi on the arm, assessed by a nurse interviewer, and those who (b) had two or more naevi of 2 mm or greater diameter on the arm, assessed by a doctor, had similar risks. 59 60 This suggests that a simple method, based on a limited examination by a lay person, or even on self reporting, may be as valuable at identifying subjects at high risk as a time consuming full examination by a dermatologist. However, whether any of these methods is a sufficiently good risk indicator to be used on a large scale is unclear. If the Australian criterion of five or more raised moles were applied 7% of the population who have 28% of the melanomas, but a 10 year risk of only 1'8%, would be isolated. Thus for a population of one million, identification of 70 000 subjects and surveillance for 10 years might lead to the early diagnosis of melanoma in 1260 subjects, but 68740 would have had the surveillance unnecessarily. Whether this balance is acceptable will depend on the resources available. An analogy can be made with the treatment of mild hypertension. The 10 year risk of death from cardiovascular disease in mildly hypertensive subjects in a large Australian trial was 2'6%,61 somewhat similar to the risk of incident melanoma in a high risk group. The treatment of mild hypertension by drugs and regular visits to a general practitioner, which is generally accepted as worthwhile, may be broadly comparable in time, cost, and benefit to regular skin surveillance by general practitioners.
A more extensive analysis using the Western Australia case-control study" shows that while the number of naevi was the major predictor of risk, additional discrimination power was given by four other variables: arrival in Australia before 10 years of age, history of nonmelanoma skin cancer, time spent outdoors in summer between ages 10 and 24, and family history of melanoma. The reproducibility of the more complex questions outside the context of a well designed case-control study using trained interviewers would need to be tested, however, and the difference in performance of the chosen model over a one factor model is moderate. Thus the suggested five factor model isolated, from an independent sample of 111 case-control pairs, 54% of patients with melanoma and 16% of controls; the single factor of "five or more raised naevi on the arms" isolated 27% of cases and 7% of controls in the second sample. For screening purposes, simplicity and reproducibility are paramount, and the extra information given by a more complex model may not be a valuable addition in wider application.
Similarly, Marrett et al have used the results of their case-control study in southern Ontario to assess the identification of subjects at high risk." They found the number of naevi, hair colour, freckles, and tendency to sunburn were predictive of risk, and the selection of, for example, 5% of the population would isolate subjects contributing 25% of all melanomas. These results are similar to those from the other studies noted.
MacKie et al in Scotland recommend the use of risk factor charts based on the number of pigmented naevi more than 2 mm in diameter, freckling tendency, number of clinically atypical naevi, and a history of severe sunburn." A multiple regression model gave a relative risk of over 500 for men and 180 for women, comparing subjects who had all these characteristics with those who had none. The distribution of the population in terms of these factors is not given, however, so absolute rates for different categories cannot be calculated. The accuracy of the predictive model and the validity of application of the measures given need to be assessed in an independent sample, as they were in Western Australia."
COSTS AND POTENTIAL HAZARDS FROM SCREENING
Demand on health services and costs
The effect of public education campaigns on the volume of referrals has been documented. In Nottingham, after a brief media based public education campaign in the early summer of 1987, the number of referrals to hospital clinics each week rose from the previous average of 23 to 55 over the following three months, and three half day sessions a week were needed to meet the demand." In the neighbouring area of Leicestershire the number of new patients seen each week rose from 12 to 55. 22 In another area with a similar campaign the numbers of patients coming to a group of 29 general practitioners with a suspect pigmented lesion rose from two to four a day." In none of these areas was it possible to demonstrate a statistically significant improvement in the depth distribution of melanoma, owing to the limited numbers. Ellman reports that the 1987 publicity campaign held in England was not continued in 1988 because of the strain put on services; the referral clinics were filled to cap acity."
The effects of general skin examinations done as screening on the number and cost of further follow up visits, hospital referrals, and biopsy rates, are unknown. It has been estimated in New Zealand that if general practitioners did an annual full skin examination for adults aged 35 to 64 in their practices they would need to commit nearly 5% of their total clinical time to this procedure alone. 50 Koh et 29 al comment that about 85% of the population of the United States visits a doctor every two years, and routine physical examinations are widely used; however, they also note that examinations by non-dermatologists may not be adequate for detection of skin cancers." The costs of further investigation and the costs for treatment of minor lesions which would not be treated outside the screening programme also need to be included.
Problems of follow up
As noted above, many of those advised to have further assessment or treatment in the United States screening programmes did not do so. It is relevant to note that casual screening in other situations -for example, testing for high blood pressure in shopping centres, has been discredited because it has been shown that few of those screened positive obtain the necessary follow up information and suitable long term treatment, and therefore that such screening can both cause anxiety and distress in those who screen positive but do not have ready access to appropriate facilities, and perhaps undue complacency in those who screen negative. Similar questions have been raised about cholesterol screening done in an unstructured manner.
Compliance
Screening must be acceptable to the population at risk. This may well be true at least in high risk areas such as Australia but has not been tested in large scale programmes, and would probably in practice depend considerably on the costs incurred. The procedure can certainly be regarded as free from major discomfort or side effects, though not free from inconvenience.
Options for evaluation
Several different designs for evaluation studies will be described, but some general issues need attention in any programme.
GENERAL ISSUES FOR ANY INTERVENTION STUDY
The intervention to be offered There are two main screening procedures which seem to have potential in most societies. Firstly, screening by a primary care doctor, preferably the patient's regular doctor, or by a nurse or other health worker, working with the doctor or independently. This should be a full body examination (see above). A systematic protocol for the examination, recording of the findings, and a systematic clinical history recorded by the subject or the examiner need to be developed and piloted in the society in which the trial is to be done. The screening system should be specifically designed to identify lesions sufficiently suspicious that they require biopsy or referral, rather than to diagnose particular lesions.
Secondly, self screening, probably combined with screening of family members by other family members. A number of preliminary protocols are available, and pilot work would need to be done to define an appropriate protocol and to test it for acceptability in the relevant society.
Ideally, a study could measure the effects of either of these screening systems alone and of the combination. A two by two factorial design should be considered when sample size calculations are made; a three arm trial is an alternative but may be less efficient. Even achieving adequate sample size for a single comparison will be a major challenge, however, and the greatest contrast would be between no screening offered and the offer of self screening combined with primary care screening.
The age range at risk is likely to be quite wide -for example, 45--69, and both sexes need inclusion. There are no available data on the variation in the performance of screening by age or sex. The most relevant determinant of the appropriate target group is the incidence of deep (> 1·5 mm) melanoma by age and sex.
There are also no useful data on the ideal frequency of screening. Annual screening is likely to be the most readily promoted and should probably be tested first for that reason alone. It would be important to have at least two rounds of screening to allow a comparison between the first ("prevalence") screen and the rescreen. A comparison of the prevalence of lesions found at the first screen with the previous annual incidence would give a first estimate of lead time which would be useful, a high ratio of prevalence to incidence being encouraging. No data on which an estimate of this can be based are yet available.
Investigation of subjects positive on screening
Specific protocols need to be developed for subjects screened positive, that is with one or more lesions regarded as suspicious. Facilities for biopsy and referral will have to be readily available. It may be possible to define an intermediate group of lesions regarded as abnormal but not needing biopsy; for these a specific follow up protocol, probably with photographic recording to allow assessment of changes, may be valuable. The scope of the screening programme would end with the biopsy diagnosis, from which routine clinical treatment would take over, that treatment being done by the hospital and doctor of the patient's choice; however, the trial provides a stimulus for the development and implementation of agreed policies for the management of newly found lesions.
Outcome measures
(1) Death from melanoma Total ascertainment of deaths in subjects offered the intervention and in the comparison groups is essential, and an independent blind review of deaths certified as being due to melanoma or causes with which it might be confused would be valuable. 
Ethical issues
The current situation in most societies is that screening for melanoma (as distinct from programmes to promote increasing awareness of early signs) is not specifically covered by public sector health providers. Screening is recommended by many groups, however, as noted above, whose opinions impact on the general media even in other countries. Individual primary care doctors and specialists are likely to encourage screening of various sorts in various ways. There should be no ethical issue in regard to the comparison group as they have their normal medical care. Those in the intervention group need to be given balanced information about the potential benefits and hazards of the screening being offered. This allows them to give informed consent when they appear for a screening examination. Access to routine incidence and mortality data is already accepted in most societies for appropriate research purposes, with appropriate ethical and confidentiality controls. Special surveys requesting more detailed information would be mounted as required, and these would request individual consent before participation. Indeed, a more critical ethical argument is whether it is appropriate to continue the current ambiguous situation in regard to melanoma screening without an attempt at appropriate evaluation, as without a trial such as that being considered here adequate knowledge of the impact of screening will not be obtained.
RANDOMISED TRIALS OF GENERAL POPULATION SCREENING
These designs require a source population for whom identification and address data are known, and cancer incidence and mortality registration are of high quality. In many societies identification of a target group can be made through a population listing such as an electoral roll (for example, Australia and New Zealand) or population listings used for health Follow through routine data for incidence. mortality Follow through routine data for incidence. mortality insurance, primary care, or other purposes (for example, Canada, the United Kingdom, Scandinavian and some other European countries), which give names, addresses, and ages, but appropriate approval must be granted.
Design 2: Trial using community based randomisation
To avoid these problems, in design 2 (fig 2) the first step would be to identify potential eligible "communities", which might be geographical communities, workplaces, primary care practices, or other identifiable groups. These communities would be randomised into a group to be offered screening and a comparison group, by simple randomisation, or with stratification by such variables as size of the community, Design 1: Trial based on individual randomisation A trial based on individual randomisation is theoretically the simplest and most powerful study design. A population listing would be used to identify subjects of an appropriate age range who would then be individually randomised (fig 1) . Those randomised to the intervention group would be offered screening, whereas the comparison group would be given no offer of screening. The primary outcome would be mortality, assessed through the routine data systems, with incidence by depth as an interim outcome. Surveys of subsets of both the intervention and comparison groups would be made to assess rates of skin biopsy, measures of anxiety, and attitudes and experiences from the programme.
This design is efficient and simple to interpret. As the control group is a genuine nonintervention group the comparison is between the defined intervention and current normal care. Compliance within the randomised group may be relatively low, and the need for analysis to compare all those randomised to the intervention group with those in the comparison group may make it more difficult to assess the positive impact of the intervention. It would be argued, however, that the relevant management question is the success of a proposed population based intervention strategy, given that the response rate to this is taken into account. This first design has been used in several large scale cancer screening trials, such as the New York and Swedish studies of breast cancer screening.67 sa Although theoretically attractive, this design may be logistically difficult. It requires that some subjects are offered screening, whereas their neighbours or other members of their family living near by might not be. It implies that screening can be offered to everybody in the population at a consistent standard. If primary care doctors were the screeners they would be asked to screen certain of their patients but not others. The contamination of the comparison group might be considerable, creating demand for screening within the comparison group. Individual randomisation may be most appropriate where screening is done by a team or person outside the normal health care system, and where a number of interventions are offered, so that those subjects not offered skin screening would be offered other interventions or education.
Surveys of samples for other outcomes
Randomise subjects
Randomise communities
Surveys of samples for other outcomes
Surveys of samples for other outcomes type of medical care provisron, geographical location, or socioeconomic variables. If there were a large number of separate eligible communities simple randomisation might suffice. If the number were smaller, stratification or indeed allocation of eligible communities into pairs or triplets where particular communities within each matched set were randomised to the intervention group would be more efficient.
It is still essential to use a population listing to collect individually linked incidence and mortality data on all members of the initial study groups. Screening could be offered through primary care doctors, with the great advantage that those in the intervention communities would be asked to offer screening to all their eligible patients. Alternatively, specific screening clinics, using doctors or nurses, could be made available; but it would still be much easier to offer this service to all in defined communities. Follow up and outcome assessment would be as described in design 1, using routine data systems and also specific ad hoc surveys of samples.
The main advantage over individual randomisation is that it should be logistically more feasible, and the likelihood of severe contamination between the intervention and comparison groups could be minimised. The main disadvantage is the sample size, as the cluster randomisation technique requires substantially greater numbers." Another severe problem arises if the number of eligible communities is relatively small, as the likelihood of there still being systematic differences between those offered screening and those in the comparison group may be considerable, weakening the advantages of the randomisation.
Size of study and costs: designs 1 and 2 It is obviously impossible to give more than a very general indication of the size and costs of such trials as these will depend on local conditions. The following formulation was prepared for Canada, which has a moderate incidence: cumulative rate to age 74 is 0·7% compared with United Kingdom 0'4, Sweden 1'0, Australia (New South Wales) 2'6. 70 Sample sizes depend on the number of events -that is, Estimated" approximate cost of randomized trial using individual randomisation, offering screening to 260000 subjects in two annual rounds, with three years' follow up; assumes follow up of control group at no extra cost • Cost estimates are only for illustration and obviously will depend on local conditions. Elwood deaths from melanoma, which occur. We have used incidence, depth distribution, and data on survival by depth to calculate the expected deaths from melanoma in a cohort of subjects free from disease at the beginning of observation. For the age range 45-64 there would be about 120 incident cases and 20 deaths from melanoma for each 100000 such subjects. To detect a one third reduction in death from melanoma -that is, a relative risk of 0·67 (or 1-5), with 5% two sided significance and 90% power, requires an expected number of 88·1 events in each group." This could be achieved by two groups of 500 000 subjects aged 40-64, or 400 000 aged 50-74. It could be argued that a single sided significance test is appropriate as the action decisions based on a null result or on a detrimental effect of screening are the same, which reduces the size of the study needed, but a smaller projected risk difference, higher power, or consideration of subgroups will increase it.
If it is possible to obtain routine incidence and mortality data for a large population an efficient design would compare a smaller group of subjects offered screening with a much larger control group, being all those members of the community of the appropriate age range who are not offered screening. A design with 10 controls for each case reduces the expected number of events in the intervention group to 48, for the same (two sided) criteria as given above, so a design with 260 000 offered screening and 2·6 million comparison subjects not offered screening, using the 45--69 age range, gives the same power characteristics as the design noted above. Such a design would seem to have potential in many societies.
Costs will depend primarily on the unit costs of the invitation process, the screening itself, and the investigation of subjects screening positive; the other most critical factor is the proportion of those screened requiring follow up. Based on some arbitrary unit cost estimates of $2 for invitation, $10 for screening, $100 for follow up, and a 5% positivity rate, the overall total cost of a programme which would include two annual screening rounds and a further three years of passive follow up is estimated as around $10.7 million over the five years (table) . Of this, $8.3 million is the cost of screening and investigation of subjects screening positive. It could well be argued that these costs are related to the provision of a new health care service, and in the absence of evaluation of skin cancer screening may well be incurred by default by a health care service which permits the ad hoc development of skin cancer screening. The remaining cost of $2.4 million over five years, which would be regarded as a research cost, may well be considered not unrealistic. If higher unit costs or positivity rate are assumed the total cost goes up greatly, so these critical items need to be looked at carefully.
Sample size for design 2 will be increased because of the cluster sampling technique used, and the extent of the increase will depend on the number of communities and their size, and on the intercommunity varia-tion in melanoma death rate both in the screened and the unscreened populations. Preliminary work using existing data should be able to provide the information on community size and distribution, and the variation in melanoma death rates over a suitable period before screening. It might be expected that the variation in melanoma death rates between individual screened communities would be somewhat larger than that in the absence of screening, as variation in the response and perhaps the efficacy of screening between communities will be added to the other factors producing variation between communities.
Design 3: Screening trial based on individual randomisation, with pre-randomisation consent Here, information on the programme is given to all subjects, and consent is obtained before individual randomisation. Such a design was used in the Canadian breast screening trial. 72 The design is closer to the classical small scale clinical trial where all subjects are given full information before agreeing to participate in the randomisation process. As noted above, however, a design of type 1, in which consent is obtained only from those offered the intervention, is also ethically acceptable. There are several scientific and logistical problems with consent before randomisation. The information given before randomisation may influence behaviours and attitudes, so that those who are randomly allocated to the comparison group Offer trial and obtain informed consent may well change their screening behaviour considerably. It would be unacceptable not to offer some potential benefit to this comparison group, so an intervention such as an educational programme or a single screening would need to be offered. This would weaken the design of the study, as the critical question is not which of several interventions is more useful but whether a particular screening programme is an improvement on current normal care. If some intervention were offered to both intervention and comparison groups the expected difference in ultimate outcome would be less, so the sample size needs to be larger, and the question answered by the trial is modified. Another major cost is introduced in approaching all subjects initially to obtain their consent before randomisation. One advantage is that the drop out rate in the intervention group may be lower than in design 1 as consent was already obtained before randomisation. Because of the extra costs of this design as compared with design 1, and the scientific problems it introduces, this design is not explored further. It is difficult to see logistically how a community intervention design similar to design 2 can be introduced which requires consent before randomisation.
Conclusion: for a general population screening trial
Thus a suggested design for a moderate to high incidence area would be a trial, randomised by individual or group, assessing at least two annual rounds of both screening by doctor and self screening (ideally by a factorial design), for adults aged 45-69, with mortality over several years' follow up as the critical outcome. In an area with good data systems such a study could compare screening offered to some 260 000 subjects with 10 times that number of controls passively followed up, with 90% power to detect a one third reduction in mortality. A general assessment of costs over five years gave estimates of $8.3 million for the screening programme and $2.4 million for the evaluation.
Follow through routine data for incidence, mortality 
RANDOMISED TRIALS OF SCREENING HIGH RISK SUBJECTS
Design 4: Screening trial based on high risk subjects, selected by an objective process Design 4 assesses the effect of a screening programme in a group selected to be at higher risk than average (fig 3) . This might either be a selected group regarded as having substantially higher risk than average, or a less stringently selected group, excluding from the trial those at a rather low risk of melanoma. From a general population defined as above, a survey system would be used to distinguish those at moderate to high risk of melanoma. This might be by a self assessment process or, at greater expense, a preliminary screening method, such as a limited examination and a questionnaire given by a lay interviewer. The production and validity assessment of this
Surveys of samples for other outcomes
Randomise participants
Surveys of samples for other outcomes initial screening method is of critical importance. Those who complete this and are assessed at an appropriate level of risk are then randomised. The intervention group would be offered the screening procedure. It would be unacceptable not to offer some degree of assessment, screening, or education to those randomly allocated to the comparison group, which complicates the scientific design and increases cost.
Size of study and costs for design 4 The various risk criteria described above suggest that it would be possible to select about 7% of the population who would have 35 % of all the melanoma -that is, an incidence five times that of the average population. At this incidence, adequate numbers of subjects (for the criteria given under design 1) would be obtained from a screened sample of 100 000 and a control high risk sample of the same size. If a 60% response to this initial questionnaire is assumed the initial target population would need to be six million, of whom 3 600 000 respond and, of those, 250000 would be at high risk. Then if a relatively high compliance rate of 80% from these subjects is assumed, perhaps reasonable as they have already complied with part of the programme, the two groups of 100000 would be defined and followed up.
The costs of such a programme, compared with screening of the general population, are therefore reduced as fewer subjects are screened, though the positivity rate will probably be higher. The efficiency of this design will depend most critically on the costs of obtaining a valid selection of subjects at high risk. If the same unit costs as mentioned earlier are used the costs for the screening and follow up for 100000 subjects would be $4.9 million, assuming the non-intervention group in this high risk situation could be followed up passively at minimal costs. If the non-intervention group require active follow up at a cost similar to that of the screened group, this cost doubles. To select subjects at high risk the source population of six million subjects must be assessed; even a cost of $1 per subject raises the cost of this whole trial to $ 10.9 million, similar to the cost of design 1.
Design 5: Trial of screening of high risk subjects after community randomisation
The concept of offering screening only to subjects at high risk might be combined with a community randomisation design, but it introduces another complexity. As the comparison is between the melanoma death rate in communities randomised to the high risk screening group compared with comparison communities, the trial assesses the impact of screening subjects at high risk on the total melanoma death rate for that community. This is a relevant question but difficult to answer as the impact of the high risk screening is diluted within the whole community, and the differences in effect may be small.
Elwood
Design 6: Trial of screening in a volunteer population A trial could be mounted simply in volunteers who come forward to open access screening centres, recruited by media publicity. This is logically the simplest design, though its interpretation may be complex. Those who attend are likely to have a substantially higher risk of melanoma. Difficulties are that the attendees are likely to be younger than the main risk groups, and a high proportion may already have lesions about which they are concerned. The question of the inclusion of such people in the analysis may be quite difficult. The great advantage of this design may be in cost, as no objective preliminary assessment is used, and the compliance rate from those who voluntarily attend would be high. There is some difficulty in interpretation as the selection forces which determine who volunteers may compromise the generalisation of the results, but collection of demographic and clinical data on volunteers and on samples of the source populations may allow these effects to be assessed. It is unreasonable to randomise some of these volunteers into a no-intervention group. As a minimum, an initial screen may be needed for all, and the trial would compare subsequent screens with none, different frequencies of screening, or further screening by health professionals with some form of self screening. As these contrasts would be expected to have a smaller marginal benefit than a comparison of clinical screening versus no intervention, the sample size would need to be larger.
Size and costs: design 6:
If it is assumed that those coming forward would be of similar risk to those subjects selected in design 4, the screening costs for the intervention group will be similar. The recruitment uses only media publicity and is therefore inexpensive. However, some intervention would need to be offered to the comparison group. If this were a first screen only, the costs of the whole study would be some $7 million based on two groups of 100 000, making it the least expensive of the options considered. If the intervention in the comparison group was even simpler, such as an educational package or a self screening guide, the costs would be lower; however, the need to increase the sample size to relate to the smaller predicted mortality difference would increase this.
NON-RANDOMISED STUDIES
Non-randomised studies comparing population groups
The next strongest design short of a randomised trial is comparison of geographical areas or defined communities where a particular screening programme is offered, with areas in which no particular programme is offered. Such studies can be considered at two contrasting levels of complexity. If data are not available on individuals the comparison made is between the extent of screening and the mortality, or its change compared with the baseline mortality before screening in different communities. Data on the incidence of melanoma and depth distribution would be also obtained. This is a weak design as differences in individual risk factors cannot be dealt with, and information on intermediate end pointssuch as the sensitivity, specificity, and other characteristics of the screening test -requires particular substudies. An analogue would be the analysis of changes in cervical cancer mortality in Canadian provinces compared with the extent of cervical screening," which provided a useful but not definitive contribution to knowledge on cervical screening. The studies of the trends in melanoma incidence and mortality in Scotland are also of this design, without a specified comparison population. 18 19 This study design is weak, and although inexpensive, the savings on evaluation may be a false economy if a reasonably intensive screening programme is to be offered.
A stronger version of this design requires individual data on the population of the screened and unscreened areas. The analogy here is the British prospective trial of breast cancer screening by mammography and by breast self examination, comparing areas using each of the interventions and control areas using neither. 74 75 Because individual data are gathered, information on the parameters of test performance, compliance, and so on is also obtained as well as information on ultimate outcome and effect on mortality and depth distribution. This design requires accurate population listings, information on who is screened and who is not, and follow up linking screening and morbidity and mortality information to population data. The study may therefore be not much less expensive than a randomised trial. Such an observational study may be more acceptable to the community and to health care planners than a randomised trial, but its weaknesses must be emphasised. Confounding by other differences and contamination by other screening processes occurring in the groups not offered the programme are major issues.
Non-randomised studies comparing screened and unscreened subjects Such designs compare those who voluntarily come for screening with the rest of the population. Compared with the designs just given, this design is considerably weaker because of self selection biases, which control for demographic and other factors is unlikely to overcome. The design is open to so many serious biases that it is unlikely to provide definitive results on the key questions of the effectiveness of screening in influencing mortality, though it might provide useful information on interim measures of test performance, cost, and so on.
Case-control studies
The case-control approach has proved useful in the evaluation of screening for breast, uterine cervix, and colorectal cancers, and is being applied to melanoma screening in Connecti- 35 cut." This study compares patients with "lethal" melanoma identified in Connecticut in 1986-91 with controls. Preliminary results show that 27% of controls report that they have ever conducted a purposeful skin examination of themselves.
This approach may well be useful. Casecontrol studies assess completed screening rather than offered screening, however, thus failing to account for compliance and selection biases in those accepting screening.":" They have been useful in assessing some important but subsidiary questions, such as the effects of screening interval, in breast cancer screening (where randomised trial evidence shows the main effect) and in cervical cancer screening, where there are also cohort studies and some elegant ecological analyses to assess the main question of effectiveness. An example of the case-control approach used on a topic with only limited randomised trial evidence" is the recent study of sigmoidoscopy.80 This study has received much attention, being claimed by some as sufficient grounds to support a screening programme."
A case-control study would require relatively modest numbers of subjects and could be inexpensive. The chief requirement is for adequate and unbiased data on previous screening for melanoma; this is difficult to obtain even for screening tests which are likely to be recorded and specifically remembered, such as mammography, and will be more difficult where the screening can be a part of a routine physical examination. Information on self screening, screening by doctors and others, the time at which such screening was done, is all important, and screening needs to be distinguished from examinations done because ofa suspected abnormality. Where the screening examination can be documented from objective sources, the reduction in mortality related to screening can be estimated by comparing subjects who have died from the disease with controls. As data on melanoma screening may be available from interview alone, only live cases can be used. A study comparing subjects with deeply invasive melanoma with controls will allow an estimate of the depth shift related to screening, but the association between a change in depth and ultimate outcome will still need to be assumed, and will be open to lead time and prevalence duration biases. Although a case-control study may not give a definitive conclusion on mortality reduction, it might provide useful data on the association between screening and a shift in depth distribution, together with data on the characteristics of patients with melanoma in regard to screening and diagnosis, and on the extent of screening in the community.
Surveys and demonstration projects
Surveys and demonstration projects offer a specific screening programme to a defined community, with evaluation of short term outcomes. Such projects do not assess whether screening reduces death from melanoma, and cannot deal with lead time or prevalence duration biases. The evaluation may assess the acceptability of the programme; the consistency and reproducibility of the screening test; the variation in screening carried out by individuals with different levels of training or working in different circumstances; the cost of screening; the positivity rate, the cost of, and compliance with, follow up; the outcome of those screening positive, not only in terms of melanoma but also in terms of other detected disease; the stage and depth distribution of melanoma in subjects screened and the treatment given. Assessment of sensitivity and specificity of the test requires follow up to assess false negatives and needs a larger sample size than for many of the above outcomes. Such demonstration projects are most useful where the value of the screening programme has already been established by more rigorous designs and the question is one of establishing a programme in a particular society"; they are not adequate for melanoma screening.
One of the easier outcome measures in such demonstration projects is the distribution of diagnosed melanomas by depth, and some health authorities have used the proportional distribution of invasive melanoma by depth as an indicator of their success in early diagnosis. A change in the proportional distribution of melanomas by depth of invasion is insufficient evidence for improvement, however, as it could be produced by the overdiagnosis of borderline lesions without any change in the incidence of deep lesions, as was seen in Queensland up to the late 1970s. 83 The demonstration of a fall in the population based incidence of deeply invasive melanoma is more helpful. 18 
CONCLUSIONS
Screening by a doctor and self screening for melanoma are currently being promoted, but in the absence of good information on their validity and usefulness.
Such promotion can be justified only if there is evidence to show that screening produces appreciably earlier diagnosis of melanoma and leads to an improved outcome and does so without an excessive increase in unnecessary anxiety, medical interventions, and morbidity. There are insufficient data at present to justify that viewpoint. Melanoma screening should therefore be regarded as an experimental procedure with attendant benefits and risks, and studies should be set up to assess its effectiveness.
If such studies are not started soon the situation is likely to become more complex in the future. Considerable interest in melanoma screening among dermatologists and voluntary bodies has been reported. Probably such interest will grow, and melanoma screening in various forms will be promoted, becoming an accepted and expensive aspect of health care. As this occurs it will become more difficult to mount evaluative studies, particularly trials, both because the comparison groups may have a considerable amount of screening of various quality and because a trial may be seen as Elwood irrelevant or even unethical if much opinion, even without evidence, favours the acceptance of such screening.
The most powerful study design which could resolve the question of the efficacy of melanoma screening is a large scale randomised trial. This would need a well coordinated proposal between several centres in one or more countries, and the cost would be substantial. The cost of a randomised trial should realistically be considered as an extra cost of evaluation, however, as the major costthat of the screening programme itself -is likely to be incurred whether or not an evaluative study is done. There is a considerable degree of interest in the development of evaluation among health care professionals, which could be developed and coordinated. There is a possibility of international collaboration, which would improve the feasibility of the study.
Area based cohort studies may also be considered. A detailed prospective trial of individual data has most of the feasibility and cost disadvantages of a randomised trial, while losing the major advantage of this design. A simpler ecological comparison is inexpensive, and would be worth putting in place whether or not other designs are also developed, using routine mortality and incidence data and surveys of the extent of screening in different communities.
Case-control studies may be limited in their ultimate interpretation. If well designed with attention to the methodological issues they may be valuable, but would not be a substitute for a more definitive design.
